About Us
Board of Directors
Ronald D. Henriksen, Chairman of the Board
Paul W. Hawran, Director
David Rickey, Director
E. Carmack Holmes, M.D., Director
Richard J. Hawkins, Director
Christopher J. Calhoun, Chief Executive Officer, Vice-Chairman and Director
Marc H. Hedrick, M.D., President and Director
Ronald D. Henriksen
Chairman of the Board
Ronald D. Henriksen joined Cytori Therapeutics as Director in October 2002 and was previously a Board member of its predecessor, StemSource, Inc. Mr. Henriksen has more than 30 years of experience in healthcare, pharmaceutical, biotechnology and consulting and venture capital industries. He currently serves as Chief Investment Officer of Twilight Ventures, LLC, and Chairman of the Board of Semafore Pharmaceuticals and EndGenitor Technologies, of which he is also Founder and President. For more than 20 years, Mr. Henriksen held executive positions with Eli Lilly, where he served as Managing Director for Brazil, Mexico and Central America, and negotiated international contracts through Lilly Business Development. Additional Board Directorships include board member positions of PreMD, Inc., and BioStorage Technologies. Mr. Henriksen received his B.S. in Industrial Administration from Iowa State University and an M.B.A. with distinction from Harvard Business School. He also served as an officer for four years in the U.S. Navy.
Back to top
Paul W. Hawran
Director
Paul W. Hawran joined Cytori Therapeutics as Director in February 2005. Mr. Hawran has served as Chief Financial Officer of Sequenom, Inc., since April 2007. He previously served as Executive Vice President and Chief Financial Officer of Neurocrine Biosciences, Inc. starting in January 2001. Prior to that, he served as Senior Vice President and Chief Financial Officer of Neurocrine Biosciences, Inc. for five years and Vice President and Chief Financial Officer for three years prior. Mr. Hawran has also held executive management positions at SmithKline Beecham (now Glaxo SmithKline), most recently as Vice President and Treasurer. Prior to joining SmithKline in 1984, he held various financial positions at Warner Communications (now Time Warner) involving corporate finance, financial planning and domestic and international budgeting and forecasting. Mr. Hawran received a B.S. in finance from St. John's University and an M.S. in taxation from Seton Hall University. He is a certified public accountant and a member of the American Institute of Certified Public Accountant.
Back to top
David Rickey
Director
David Rickey has served as a Director of Cytori Therapeutics since November 1999. From 1996 to March 2005, Mr. Rickey was President and Chief Executive Officer of Applied Micro Circuits Corporation, which provides high-performance, high-bandwidth silicon solutions for optical networks. Mr. Rickey also served as a Director and Chairman of the board of Applied Micro Circuits Corporation and currently serves on the board of AMI Semiconductor, Inc. and Netlist. Mr. Rickey holds two B.S. degrees from Marietta College and Columbia University and an M.S. from Stanford University.
Back to top
E. Carmack Holmes, M.D.
Director
E. Carmack Holmes, M.D., joined Cytori Therapeutics as Director in August 2003. Dr. Holmes serves as the Surgeon-in-Chief of the University of California Los Angeles (UCLA) Medical Center and holds the position of William P. Longmire, Jr. Professor and Chairman, Department of Surgery, UCLA School of Medicine. He joined UCLA in 1973 and has held professorial positions in the Divisions of Cardiothoracic Surgery and Surgical Oncology for over 30 years. He served as Vice-Chairman for five years prior to holding the positions of Chairman and Surgeon-in-Chief for the past ten years. Dr. Holmes is the recipient of numerous awards and grants and professional memberships include the American Surgical Association, the American College of Surgeons and the Association for Academic Surgeons. He has authored 250 medical publications throughout his career and has been an internationally invited lecturer for over 25 years. His surgical training was conducted at The Johns Hopkins University and the National Cancer Institute at the National Institutes of Health (NIH). Dr. Holmes graduated from Duke University and holds an M.D. from the University of North Carolina Medical School.
Back to top
Richard J. Hawkins
Director
Mr. Hawkins is currently the Chairman and CEO of LabNow Inc., a diagnostic device company developing rapid, point-of-care, physician office-based diagnostic testing systems. Mr. Hawkins previously founded and guided the growth of Pharmaco, a clinical drug development services company, where he served as Chairman, President, and Chief Executive Officer.
In addition, Mr. Hawkins was a founder of id2, a pharmaceutical and biotechnology research management company, Sensus Drug Development Corp., a biotechnology company that was sold to Pfizer, and Covance Biotechnology Services, and served as Chairman of the Board for LoopOne, Inc., a shipping and logistics software company. In addition to his role as Chairman of the Board for LabNow Inc., Mr. Hawkins also currently serves on the Board of Directors of Synarc, Inc. and SciClone Pharmaceuticals Inc.
Back to top
Christopher J. Calhoun
Chief Executive Officer, Vice-Chairman and Director
Marc H. Hedrick, M.D.
President and Director
Back to top